XML 19 R6.htm IDEA: XBRL DOCUMENT v3.21.1
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) - USD ($)
$ in Millions
Total
Preferred Stock [Member]
Common Stock [Member]
Add'l Paid-in Capital [Member]
Treasury Stock [Member]
Retained Earnings [Member]
Accum. Other Comp. Loss [Member]
Shareholders' Equity [Member]
Noncontrolling Interests [Member]
Beginning balance (in shares) at Dec. 31, 2019   431 9,369,000,000   3,835,000,000        
Beginning balance at Dec. 31, 2019 $ 63,447 $ 17 $ 468 $ 87,428 $ (110,801) $ 91,397 $ (5,367) $ 63,143 $ 303
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income 3,364         3,355   3,355 9
Other comprehensive income/(loss), net of tax (1,441)           (1,441) (1,441)  
Cash dividends declared, per share                  
Common stock (71)         (71)   (71)  
Preferred stock 0                
Noncontrolling interests 0                
Share-based payment transactions (in shares)     23,000,000   6,000,000        
Share-based payment transactions 44   $ 1 252 $ (209)     44  
Purchases of common stock 0                
Preferred stock conversions and redemptions (in shares)   (14)              
Preferred stock conversions and redemptions (1) $ (1)   (1)       (1)  
Other 0                
Ending balance (in shares) at Mar. 29, 2020   417 9,393,000,000   3,841,000,000        
Ending balance at Mar. 29, 2020 65,341 $ 17 $ 470 87,680 $ (111,010) 94,680 (6,808) 65,028 312
Beginning balance (in shares) at Dec. 31, 2020   0 9,407,000,000   3,840,000,000        
Beginning balance at Dec. 31, 2020 63,473 $ 0 $ 470 88,674 $ (110,988) 90,392 (5,310) [1] 63,238 235
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income 4,886         4,877   4,877 9
Other comprehensive income/(loss), net of tax 647           646 [2] 646 1
Cash dividends declared, per share                  
Common stock (84)         (84)   (84)  
Preferred stock 0                
Noncontrolling interests 0                
Share-based payment transactions (in shares)     38,000,000   11,000,000        
Share-based payment transactions (30)   $ 2 329 $ (361)     (30)  
Purchases of common stock 0                
Preferred stock conversions and redemptions 0                
Other (27)         (27)   (27)  
Ending balance (in shares) at Apr. 04, 2021   0 9,445,000,000   3,851,000,000        
Ending balance at Apr. 04, 2021 $ 68,865 $ 0 $ 472 $ 89,002 $ (111,349) $ 95,158 $ (4,664) $ 68,620 $ 245
[1] Amounts include the impact of a change in accounting principle. See Note 1C.
[2] Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments primarily include gains from the strengthening of the U.K. pound, euro and Australian dollar against the U.S. dollar, and net gains related to the impact of our net investment hedging program, partially offset by net losses from foreign currency translation adjustments related to our equity-method investment in the Consumer Healthcare JV (see Note 2B).